Cognitive · Reference
PE-22-28 for Men: What the Research Has Looked At, and What to Rule Out First
This page covers what PE-22-28 is, what research has and has not looked at, the considerations that matter for men, what a physician rules out first, and how Pepti supplies it. For the evidence benefit by benefit, see PE-22-28 benefits; for the product reference, what is PE-22-28.
Treatments mentioned
PE-22-28 has not been studied in men, or in women, because it has no human trials of any kind: everything published on it is cell and rodent work, and the live research does not report results by sex. It is a seven-amino-acid fragment that blocks the TREK-1 potassium channel in neurons, studied for antidepressant-like behaviour in mice. It is not a hormone, is not described as acting on testosterone, and is not a focus or performance compound. For men, the practical points are what else is driving low mood, any antidepressant or other serotonergic medication, and tested sport. Compounded PE-22-28 is a prescription injection, has never been evaluated by the FDA, and is not FDA approved.
If you are in crisis or thinking about harming yourself, call or text 988 in the US, or call 911, now.
This page covers what PE-22-28 is, what research has and has not looked at, the considerations that matter for men, what a physician rules out first, and how Pepti supplies it. For the evidence benefit by benefit, see PE-22-28 benefits; for the product reference, what is PE-22-28.
PE-22-28 for Men
The short answer
| Question | What the live research shows | Strength of evidence |
|---|---|---|
| Has it been studied in men specifically? | No; it has no human trials at all | None |
| What has been studied? | Antidepressant-like behaviour, neurogenesis and synapse formation in mice and rats | Animal and cell only |
| Does it affect testosterone? | Not a hormone; not described as acting on testosterone; never measured | No study either way |
| Does it improve focus or performance? | Not studied for either | None |
| Alongside an antidepressant | Never studied; the mechanism overlaps with serotonin signalling | A caution, not a known interaction |
| Fertility | Nothing in the live research | Unknown |
| Tested sport | Not named on the 2026 WADA list; the S0 section can apply | Confirm with your anti-doping organisation |
The honest summary: an interesting mechanism in mice, no human data in either sex, and a medication list that matters more than anything about being male.
PE-22-28 for Men
What PE-22-28 is, in one paragraph
PE-22-28 is a fragment of the sortilin propeptide, a 44-amino-acid piece clipped off when the body makes the sortilin receptor. Researchers in Nice, France named residues 12 to 28 of it spadin and showed it blocks TREK-1, a background potassium channel that helps set how easily a neuron fires; PE-22-28 is residues 22 to 28 only, described in Frontiers in Pharmacology in 2017. The interest started with a 2006 Nature Neuroscience paper in which mice bred without TREK-1 behaved as though given an antidepressant. It is not an antidepressant in the regulatory sense, not a stimulant and not a sedative.
PE-22-28 for Men
What research has looked at
The rodent work
The 2010 PLoS Biology paper reported antidepressant-like effects of spadin in mice across the forced-swim, tail-suspension, novelty-suppressed feeding and learned-helplessness tests after four days, with increased hippocampal neurogenesis. The 2017 paper reported PE-22-28 reproducing those effects after a four-day course, with stronger TREK-1 inhibition in cells and a half-life in the mouse of roughly a day. A 2018 ACS Chemical Neuroscience paper compared TREK-1 blockers with fluoxetine in a chronic stress model in rats, and a 2019 Neuropharmacology paper reported sortilin-derived peptides associated with improved recovery in a mouse stroke model.
What it shows. A well-characterised mechanism in rodents.
What it does not show. Anything in a man. None of the live research describes results broken down by sex, and no human has been given PE-22-28 in a published study.
The human data that does exist
A 2017 Journal of Affective Disorders paper reported the body's own sortilin propeptide being lower in the blood of patients with major depressive disorder, and a 2018 paper reported it rising after electroconvulsive therapy. These are biomarker studies, not treatment studies, and are not described as reporting results for men separately.
PE-22-28 for Men
What matters for men
Low mood has causes worth looking at first
Men often describe low mood as low drive, irritability, poor sleep or simply feeling flat, and those have causes a physician will want to think about before any peptide.
What is checked Why it matters Sleep, including apnoea Broken sleep produces low mood directly; snoring and waking unrefreshed are clues Alcohol, cannabis, stimulants, caffeine Common, reversible, and all withdraw into low mood Thyroid function An underactive thyroid produces low mood, fatigue and slowed thinking Iron and B12 Deficiency presents as low mood and mental fatigue Existing psychiatric care and medications Interaction review, and that team should be involved Suicidal thoughts or self-harm Needs urgent care, not a prescription from a website If something on that list is driving how you feel, a peptide is the wrong tool and a physician should say so. More is in peptides for anxiety and mood and peptides for men over 40.
Testosterone
PE-22-28 is not a hormone and is not described as acting on testosterone or any hormone axis. No study has measured testosterone, LH or FSH on it, so the accurate answer is "not expected to affect it, never measured." Low mood, low drive and poor sleep overlap with symptoms men attribute to testosterone; peptides for testosterone covers that question. If you are on testosterone therapy, list it on the intake; no interaction is described, but none has been studied. See can you take peptides with testosterone.
Antidepressants and other serotonergic drugs
Because PE-22-28's proposed mechanism runs through serotonin signalling, anyone on an antidepressant, a triptan, lithium, tramadol or any other serotonergic drug must say so on the intake. The combination has never been studied in people. If you are being treated for depression, the clinician managing it should be part of the decision, and no existing antidepressant should be stopped on the strength of a rodent literature.
Alcohol
Nothing in the live research looks at PE-22-28 and alcohol. Regular drinking is one of the common, reversible causes of low mood the intake asks about, which is a reason to be candid about it rather than a known interaction.
Diabetes and seizures
Cell work described PE-22-28's parent peptide increasing insulin secretion from pancreatic beta cells (Journal of Diabetes Research, 2016), so men with diabetes or on glucose-lowering medication should raise it. TREK-1 is involved in seizure protection; the rodent work found no problem, but a seizure history is discussed rather than assumed away.
Fertility
Nothing in the live research looks at PE-22-28 and male fertility in either direction, so its effect on sperm is unknown rather than shown to be nil. If you and a partner are trying to conceive, tell your physician before starting. See do peptides affect fertility.
Focus and work stress
PE-22-28's research is about mood-related behaviour in rodents, not attention or performance. Men looking for focus are usually better served by the compounds aimed at it, covered in peptides for brain fog and focus, and Selank for men and Semax for men cover the two with small human studies.
Tested sport
The 2026 WADA Prohibited List does not name PE-22-28, but its S0 section prohibits at all times any pharmacological substance not addressed elsewhere on the list and with no current approval by any governmental regulatory health authority for human therapeutic use. PE-22-28 has no such approval anywhere, so a compounded preparation can fall under S0. Check with your anti-doping organisation before starting. See peptides for athletes.
PE-22-28 for Men
What the evidence does not establish
- That PE-22-28 does anything in men, or in anyone. There are no human trials.
- An effect on testosterone, drive, sexual function or fertility. None was measured.
- An effect on focus, memory or work performance. None was studied.
- A human dose, an effect size or a timeline.
- Anything about combining it with antidepressants, testosterone or alcohol.
PE-22-28 for Men
Side effects and considerations
Nothing in the live research suggests the profile differs between men and women, and the human profile is unknown.
| What is reported or relevant | When | What to do |
|---|---|---|
| Injection-site redness, mild soreness, occasional bruising | The commonest clinical report | Rotate sites |
| Headache in the first days | Occasional | Report it if it persists |
| A change in mood that worries you or those around you | Not a described effect, always reportable | Contact your physician promptly |
| Thoughts of harming yourself | An emergency | Call or text 988, or call 911, now |
| Facial or throat swelling, difficulty breathing | Rare | Call 911 first, then tell your physician |
If you think you may have taken too much, call Poison Control at 1-800-222-1222 and message your care team. Do not skip, double or change a dose to compensate. The full detail is in PE-22-28 side effects.
PE-22-28 for Men
Where PE-22-28 stands with the FDA
PE-22-28 does not appear in Category 1, 2 or 3 of the FDA's 503A nominated-substances document updated 14 May 2026, is not on the significant-safety-risk page, and was not on the July 2026 Pharmacy Compounding Advisory Committee agenda. No safety notice, no vote either way: it has not been through the process. Compounded medications are not FDA approved.
PE-22-28 for Men
How Pepti supplies PE-22-28
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| PE-22-28 | 5 mL multi-dose vial, 2 mg/mL (10 mg per vial) | 0.25 mL (25 units) subcutaneously once daily Monday through Friday; 0.5 mg per dose, 20 doses | $219/mo |
| Selank | 5 mL multi-dose vial, 2 mg/mL (10 mg per vial) | Its own directions | $229/mo |
| Semax | 5 mL multi-dose vial, 2 mg/mL (10 mg per vial) | Its own directions | $229/mo |
Twenty weekday doses is four weeks, so refills run every 28 days, one vial per fill. The arithmetic is in PE-22-28 dosage. Your physician sets your directions after reviewing your intake, and they are printed on the vial.
Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. Vials arrive as ready-to-use multi-dose solutions with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs.
PE-22-28 for Men
Where to get PE-22-28 prescribed
PE-22-28 cannot be bought legitimately without a prescription. Research-use-only vials have no pharmacy accountable for identity, purity, sterility or concentration, and nobody reviewing your medications. The prescription route:
- Complete a free online intake covering your history, including mental health history, every medication you take (including any testosterone), whether you are drug tested, and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your care team stays reachable for questions, side effects and mood changes.
Step by step: how to get PE-22-28 prescribed online. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.
References
What this is based on.
References
- Djillani A, Pietri M, Moreno S et al.. Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity · Front Pharmacol (2017) · PMID 28955242
- Mazella J, Pétrault O, Lucas G et al.. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design · PLoS Biol (2010) · PMID 20405001
- Heurteaux C, Lucas G, Guy N et al.. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype · Nat Neurosci (2006) · PMID 16906152
- Moha Ou Maati H, Veyssiere J, Labbal F et al.. Spadin as a new antidepressant: absence of TREK-1-related side effects · Neuropharmacology (2012) · PMID 21807005
- Devader C, Khayachi A, Veyssière J et al.. In vitro and in vivo regulation of synaptogenesis by the novel antidepressant spadin · Br J Pharmacol (2015) · PMID 25598009
- Moha ou Maati H, Bourcier-Lucas C, Veyssiere J et al.. The peptidic antidepressant spadin interacts with prefrontal 5-HT(4) and mGluR(2) receptors in the control of serotonergic function · Brain Struct Funct (2016) · PMID 25233810
- Ye D, Li Y, Zhang X et al.. TREK1 channel blockade induces an antidepressant-like response synergizing with 5-HT1A receptor signaling · Eur Neuropsychopharmacol (2015) · PMID 26441141
- Hivelin C, Béraud-Dufour S, Devader C et al.. Potentiation of Calcium Influx and Insulin Secretion in Pancreatic Beta Cell by the Specific TREK-1 Blocker Spadin · J Diabetes Res (2016) · PMID 28105440
- Devader C, Roulot M, Moréno S et al.. Serum sortilin-derived propeptides concentrations are decreased in major depressive disorder patients · J Affect Disord (2017) · PMID 27838145
- Roulot M, Minelli A, Bortolomasi M et al.. Increased serum levels of sortilin-derived propeptide after electroconvulsive therapy in treatment-resistant depressed patients · Neuropsychiatr Dis Treat (2018) · PMID 30233189
- Qi X, Xu H, Wang L et al.. Comparison of Therapeutic Effects of TREK1 Blockers and Fluoxetine on Chronic Unpredicted Mild Stress Sensitive Rats · ACS Chem Neurosci (2018) · PMID 29952548
- Djillani A, Pietri M, Mazella J et al.. Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin · Pharmacol Ther (2019) · PMID 30291907
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
PE-22-28 for Men, answered.
It has not been studied in men, or in anyone; there are no human trials. Its research is rodent work on antidepressant-like behaviour, so any benefit for men is described, not established.
The same research applies to everyone: antidepressant-like behaviour, neurogenesis and synapse formation in rodents. None is male-specific and none has been tested in people. See PE-22-28 benefits.
It is not a hormone and is not described as acting on testosterone. No study has measured it either way.
No interaction is described, but none has been studied. List your testosterone therapy on the intake so your physician can review the two together.
Only if the physician who prescribes both says so. The combination has never been studied in people. Never stop an antidepressant on your own.
It has not been studied for either. Its research is about mood-related behaviour in mice. See peptides for brain fog and focus.
Nothing in the live research looks at either. If you are trying to conceive, tell your physician before starting.
No study has looked at the combination. Regular drinking is a common cause of low mood in its own right, which is why the intake asks about it.
The 2026 WADA list does not name it, but the S0 non-approved substances section can apply. Check with your anti-doping organisation.
The same as for anyone: in humans, unknown. Clinically, mostly injection-site reactions and occasionally a headache in the first days.
At Pepti, $219 a month, all-in, covering medication, physician review, refill management and shipping.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.